As of Oct 2026 · from Reg CF Offering (2026) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$184,661
Crowd $60K · Private $125K · 3 rounds since 2022
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its source
$0
−$198K
2023
$0
−$321K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2023 reviewed
FY2024 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$198,033
-$321,019
Taxes paid
$0
$0
Balance sheet
Cash
$71,225
$6,427
Accounts receivable
$0
$0
Total assets
$76,057
$20,922
Short-term debt
$13,152
$3,915
Long-term debt
$1,241,105
$1,496,726
Total liabilities
$1,254,257
$1,500,641
Other
Headcount
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note rounds
$8.0M
Valuation cap
Reg CF · Note · Mar 2026
Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Dr. Carole Spangler Vaughn holds a Ph.D. in Biophysics (Johns Hopkins University) and an MBA (University of Washington). She has spent over 25 years in the life science industry, mostly at start-ups, bringing oncology products to market.
Jessica Urban
VP Product Development, Quality & Regulatory
Jessica Urban has a Masters in Biomedical Engineering and guides devices from research to market. Jessica has almost 30 years of relevant experience including Management, Program Management, Quality, Regulatory, and Business Development.
Nathan Dale
VP Engineering
Nathan Dale is an experienced medical device engineer with nearly 30 years of expertise in product design, development, and manufacturing across implantable, disposable, and surgical technologies.
Paul Klein
VP Marketing
Paul Klein spent 40-years at GE and GE Healthcare. He is an experienced marketer with B2B and B2C expertise in durables, CPG and medical products. Paul served as General Manager of brand and advertising for the GE Appliances business.
Dr. Hope Rugo
Medical Advisor
Hope Rugo, M.D., is division chief of breast medical oncology and a professor at City of Hope, where she directs the Women’s Cancers Program and oversees national research and clinical care initiatives.
Dr. Noah Kolb
Medical Advisor
Dr. Noah Kolb is a neurologist at The University of Vermont Medical Center and assistant professor at the UVM College of Medicine Department of Neurology in Burlington, VT. His research is focused on chemotherapy-induced peripheral neuropathy.
Jennifer Gewandter
Medical Advisor
Jennifer Gewandter, PhD, MPH is an Assistant Professor in the Department of Anesthesiology and Perioperative Medicine at the University of Rochester and an Associate Director of the FDA Public-Private partnership, ACTTION.
Martin Simonetti
Board Chair
Martin Simonetti has had a long and successful career in the life sciences, serving as CFO and CEO. He is currently the CEO of PBS Biotech. He received an MS from the Univ of California, Davis and an MBA from the Univ of Santa Clara.
William (Bill) Cronin
Advisor
William (Bill) Cronin is a healthcare investor, board director, and operating executive with decades of experience supporting medical device and digital health companies through growth, capital formation, and commercialization. He serves on the
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Delinquent
Filed 0 of 1 annual reports (FY2025)
Missing: 2025
33 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
Source: SEC EDGARCIK 0001911173DELast synced Aug 17, 2026
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.
